179 related articles for article (PubMed ID: 22320243)
1. Targeting G protein and phosphorylation dependent signalling molecules for anticancer therapy.
Eswaran J
Anticancer Agents Med Chem; 2012 Jan; 12(1):2-3. PubMed ID: 22320243
[No Abstract] [Full Text] [Related]
2. The ras signalling pathway as a target in cancer therapy.
Graham K; Olson MF
Recent Results Cancer Res; 2007; 172():125-53. PubMed ID: 17607939
[No Abstract] [Full Text] [Related]
3. Caspase activity modulators as anticancer agents.
Okun I; Balakin KV; Tkachenko SE; Ivachtchenko AV
Anticancer Agents Med Chem; 2008 Apr; 8(3):322-41. PubMed ID: 18393791
[TBL] [Abstract][Full Text] [Related]
4. Editorial: Ubiquitin E3 Ligases as Molecular Targets or Tools for Advanced Cancer Therapy.
Kitagawa M
Curr Cancer Drug Targets; 2016; 16(2):100. PubMed ID: 26791134
[No Abstract] [Full Text] [Related]
5. Farnesyl transferase inhibitors.
Li T; Sparano JA
Cancer Invest; 2008 Aug; 26(7):653-61. PubMed ID: 18665473
[No Abstract] [Full Text] [Related]
6. Targeting Rho GTPase signaling for cancer therapy.
Mardilovich K; Olson MF; Baugh M
Future Oncol; 2012 Feb; 8(2):165-77. PubMed ID: 22335581
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological inhibitors of the ERK signaling pathway: application as anticancer drugs.
Kohno M; Pouyssegur J
Prog Cell Cycle Res; 2003; 5():219-24. PubMed ID: 14593716
[TBL] [Abstract][Full Text] [Related]
8. The role of Pin1 in the development and treatment of cancer.
Min SH; Zhou XZ; Lu KP
Arch Pharm Res; 2016 Dec; 39(12):1609-1620. PubMed ID: 27572155
[TBL] [Abstract][Full Text] [Related]
9. Cell division on-off switches sought as targets for cancer drugs.
Hampton T
JAMA; 2005 Apr; 293(15):1847. PubMed ID: 15840846
[No Abstract] [Full Text] [Related]
10. Opinion: Searching for the elusive targets of farnesyltransferase inhibitors.
Sebti SM; Der CJ
Nat Rev Cancer; 2003 Dec; 3(12):945-51. PubMed ID: 14737124
[No Abstract] [Full Text] [Related]
11. Re: preclinical and clinical development of cyclin-dependent kinase modulators.
Darzynkiewicz Z
J Natl Cancer Inst; 2000 Jul; 92(14):1184-5. PubMed ID: 10904096
[No Abstract] [Full Text] [Related]
12. Immunohistochemical determination of EGFR-tyrosine kinase inhibition in clinical samples.
Malik SN; Bedolla RG; Hidalgo M; Brattain MG; Kreisberg JI
Methods Mol Med; 2003; 85():135-40. PubMed ID: 12710204
[No Abstract] [Full Text] [Related]
13. Mechanisms of drug inhibition of signalling molecules.
Sebolt-Leopold JS; English JM
Nature; 2006 May; 441(7092):457-62. PubMed ID: 16724058
[TBL] [Abstract][Full Text] [Related]
14. Impact of oncogenic protein tyrosine phosphatases in cancer.
Hardy S; Julien SG; Tremblay ML
Anticancer Agents Med Chem; 2012 Jan; 12(1):4-18. PubMed ID: 21707506
[TBL] [Abstract][Full Text] [Related]
15. Issues and progress with protein kinase inhibitors for cancer treatment.
Dancey J; Sausville EA
Nat Rev Drug Discov; 2003 Apr; 2(4):296-313. PubMed ID: 12669029
[TBL] [Abstract][Full Text] [Related]
16. Basis and importance of Src as a target in cancer.
Levin VA
Cancer Treat Res; 2004; 119():89-119. PubMed ID: 15164875
[No Abstract] [Full Text] [Related]
17. Phosphorylation-specific prolyl isomerase Pin1 as a new diagnostic and therapeutic target for cancer.
Finn G; Lu KP
Curr Cancer Drug Targets; 2008 May; 8(3):223-9. PubMed ID: 18473735
[TBL] [Abstract][Full Text] [Related]
18. Fortifying p53 - beyond Mdm2 inhibitors.
Sriraman A; Li Y; Dobbelstein M
Aging (Albany NY); 2016 Sep; 8(9):1836-1837. PubMed ID: 27688014
[No Abstract] [Full Text] [Related]
19. Recent discovery of non-nucleobase thymidine phosphorylase inhibitors targeting cancer.
Bera H; Chigurupati S
Eur J Med Chem; 2016 Nov; 124():992-1003. PubMed ID: 27783978
[TBL] [Abstract][Full Text] [Related]
20. Targeting cancer metabolism to develop human lactate dehydrogenase (hLDH)5 inhibitors.
Zhang SL; He Y; Tam KY
Drug Discov Today; 2018 Jul; 23(7):1407-1415. PubMed ID: 29750903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
